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Abstract
Exposure to estrogenic compounds during critical
periods of fetal development could result in adverse
effects on the development of reproductive organs
that are not apparent until later in life. Bisphenol A
(BPA), which is employed in the manufacture of a wide
range of consumer products, is a prime candidate for
endocrine disruption. We examined BPA to address
the question of whether in utero exposure affects the
uterus of the offspring and studied the expression and
distribution of the estrogen receptors alpha (ERa) and
beta (ERh), because estrogens influence the develop-
ment, growth, and function of the uterus through both
receptors. Gravid Sprague-Dawley dams were admin-
istered by gavage either 0.1 or 50 mg/kg per day BPA
or 0.2 mg/kg per day 17a-ethinyl estradiol (EE2) as
reference dose on gestation days 6 through 21. Female
offspring were killed in estrus. Uterine morphologic
changes as well as ERa and ERh distribution and
expression were measured by immunohistochemistry
and Western blot analysis. Striking morphologic
changes were observed in the uterine epithelium of
postpubertal offspring during estrus of the in utero
BPA-treated animals (the thickness of the total epi-
thelium was significantly reduced). ERa expression
was increased in the 50-mg BPA and EE2-treated
group. In contrast, we observed significantly de-
creased ERh expression in all BPA- and EE2-treated
animals when compared with the control. In summary,
these results clearly indicate that in utero exposure
of rats to BPA promotes uterine disruption in off-
spring. We hypothesize that the uterine disruption
could possibly be provoked by a dysregulation of
ERa and ERh.
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Introduction
Endocrine-disrupting industrial chemicals (EDCs) are re-
leased into the environment and interfere with normal
hormonal processes. Many researchers hypothesize that
inadvertent and untimely exposure to these EDCs during
critical periods of development, i.e., early postnatal or in utero,
may adversely affect the reproductive and general health,
growth, and development in both wildlife and humans [1,2].
The origins of the endocrine disrupter hypothesis may be
traced to reports on adolescent daughters born to women who
had taken the highly potent synthetic estrogen diethylstilbestrol
(DES) during pregnancy. The negative consequences of this
practice began to emerge when studies reported that these
daughters developed a wide range of reproductive tract abnor-
malities, including a rare form of vaginal cancer, vaginal
adenocarcinoma, and uterine malformations, including hypo-
plasia and a T-shaped uterus [3,4].
Bisphenol A (BPA) is a monomer composed of two unsat-
urated phenolic rings that resemble DES. In vitro studies
demonstrated that BPA binds to the estrogen receptors, indu-
ces estrogen-dependent gene expression/responses, and is
weakly estrogenic when compared with 17b-estradiol or DES
[5–8]. BPA is among those estrogenic industrial compounds
that are in widespread use. BPA is used in the production of
epoxy, polyester-styrene, and polycarbonate resins, which are
used for the manufacture of dental fillings, baby bottles, and
food packaging. The ability of BPA to migrate from polymer to
food has been described [9–11]. Leaching of BPA increases
with repeated use or exposure to high heat of the polycarbon-
ate products [9,11–14]. These data indicated a likely exposure
of wildlife and humans to BPA. Indeed, we detected parent
BPA in pregnant women and their fetuses [15]. Exposure levels
of parent BPA were found within a range typical of those used
in recent animal studies [16] and which were shown to be toxic
to reproductive organs of male and female offspring. Further-
more, BPA was present in human serum and follicular fluid, as
well as in full-term amniotic fluid [17]. BPA has been widely
discussed as a prime candidate for endocrine disruption.
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Minuscule amounts of EDCs were shown to alter the
reproductive organs of developing mice, sparking alarm
within the scientific community and regulatory agencies.
Particularly, studies have shown that low doses of BPA could
alter reproductive organs of developing rodents [18–28].
Additional relevant studies reported findings where BPA is
a potent meiotic aneugen [29], and at very low doses BPA
induces proliferation of human prostate cancer cells through
binding to a mutant form of the androgen receptor found in
some prostate tumors [30]. Alarmed about the implications of
these results, some laboratories, mainly industrial ones, tried
to reproduce these data but failed [31–36]. However, in
addition to finding no low-dose effects of BPA, no effects of
their positive control chemicals, DES, estradiol, and ethinyl
estradiol, were found. These discrepancies between the
studies may be attributable to variable sensitivity to estro-
genic chemicals by laboratory animals as well as the type of
feed used in the experiment [37]. For example, one study
demonstrated that rodent strains can vary dramatically in
their response to estrogenic compounds [38]. Furthermore,
the issues of dose and binding affinities to the estrogen
receptors (ERs) seem to be the heart of the controversy
regarding xenoestrogens.
Pointing to these uncertainties [39] and the intense public
interest in the concept that inadvertent and untimely expo-
sure to BPA may adversely affect the reproductive and
general health. We thus started to investigate the mecha-
nisms of estrogen action in fetal rodents, because the
earliest life stages are the most sensitive to EDCs, and
prenatal exposure to EDCs leads to developmental effects
that may not be detectable until sexual maturity.
For that reason, we examined the effects of in utero
treatment with BPA [26,40] because prenatal exposure of
rodents to EDCs causes a variety of abnormalities in the
reproductive tract, specifically on the uterus, which are
similar to the abnormalities in humans. In our previous
studies gravid Sprague-Dawley dams were administered
by gavage either 50 or 0.1 mg/kg per day BPA on gestation
days 6 through 21 [26,40]. We used these two different
doses of BPA to treat our animals because, for risk-assess-
ment purposes, the Society of the Plastic Industry has
recommended using 50 mg/kg per day as the no effect dose
level (NOEL), and the reproductive and offspring toxicity
no adverse effect dose level (NOAEL) was recently identified
as 750 ppm (50 mg/kg per day) of BPA [33]. Doses below
50 mg/kg per day would thus be considered to fall within the
‘‘low-dose’’ range.
Here, we specifically addressed the question of whether
in utero exposure to BPA alters the uterus of the offspring
because the uterus is a major target organ for circulating
hormones. The uterus is composed of different cell types
(stroma, epithelial, and smooth muscle cells) that undergo
continuous changes of differentiation and proliferation in
response to changes of circulating estrogens [41,42]. We
hypothesize, therefore, that in utero exposure of the devel-
oping fetus to exogenous estrogens might have a major
impact on the uterus leading to long-term deleterious effects.
We studied, especially, expression and distribution of the
estrogen receptors alpha (ERa) and beta (ERb) because
estrogens influence the development, growth, and function
of the uterus through both receptors. Although it has been
demonstrated that ERa plays a major role in the differentia-
tion and proliferation of the uterine epithelium, it has recently
been demonstrated that ERb can modulate the effects of the
uterine dominant ERa and, therefore, has an antiproliferative
function in the uterus [43].
Materials and Methods
Female Sprague-Dawley rats with sperm-positive vaginal
smears were treated with either 2% cornstarch (Mondamin)
at 10 ml/kg per day, BPA at 0.1 or 50 mg/kg per day, or
17a-ethinyl estradiol (EE2) at 0.2 mg/kg per day. Cornstarch
served as the vehicle for BPA and pharmacological-grade
peanut oil was used as the vehicle for EE2. The gravid dams
were treated by gavage on gestation days 6 through 21.
Intact female offspring were maintained on a 12:12-hour
light–dark cycle (light turned on at 6:00 A.M.), and beginning
at approximately 3 months of age, estrous-cycle stage was
determined by vaginal swabbing for 3 weeks. Each estrus
group contained 6 offspring in the cornstarch group, 6
offspring in the 0.1 mg/kg per day and 6 offspring in the
50 mg/kg per day BPA group, as well as 6 offspring in the
0.2 mg/kg per day EE2 group. At approximately 4 months of
age, female offspring were killed by decapitation in estrus
between 9:30 and 16:00 hours. Body and reproductive organ
weight were determined. Animals were maintained in accor-
dance with the Guide for the Care and Use of Laboratory
Animals by the Physiological Society of Germany. BPA was
purchased from Sigma-Aldrich Chemicals GmbH (Stein-
heim, Germany) and 17-a ethinyl estradiol from Aldrich
Chemical Company (Milwaukee, WI).
Histology
Uterine tissue was fixed in methacarn solution. The tissue
sections (3 mm thick) were deparaffinized and rehydrated in
distilled water. For histochemical stains, the dewaxed sec-
tions were stained with 1.0% wt/vol Mayer’s hematoxylin and
0.5% wt/vol eosin.
Immunohistochemistry
Uterine tissue was fixed in methacarn solution. The tissue
sections (3 mm thick) were deparaffinized,mounted onSuper-
frost glass slides, and rehydrated in distilled water. Antigenic
epitopes were demasked by boiling sections for 20minutes in
citrate buffer (0.01 M, pH 6.0) in a conventional pressure
cooker. Briefly, the sections were treated with 0.5% hydrogen
peroxide in methanol for 30 minutes, blocked with 2.5% of
normal horse serum (Alexis, Gruenberg, Germany) for 30
minutes and incubated with avidin and biotin (Vectorshield;
Alexis) for 15 minutes. Sections were reacted with specific
primary polyclonal antibodies against ERa (MC-20, sc-542;
Santa Cruz, Heidelberg, Germany) at a 1:150 dilution or ERb
(PA1-311, Affinity Bioreagents, Golden, CO) at a 1:500 dilu-
tion for 2 hours in a humid chamber at room temperature,
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followed by incubation with biotinylated polyclonal antibodies
(Vector Staining Kits; Alexis). Then, the reaction products
were visualized according to manufacturer’s instructions
(R.T.U. Vectastain Universal Elite Kit, Alexis) using 3-ami-
no-9-ethylcarbazole as the chromagen (Sigma Immuno
Chemicals, Munich, Germany) and covered with Mayer’s
hematoxylin for counterstaining.
Negative control reactions for ERa or ERb immunostain-
ing were conducted on uterine tissue either with substitution
of PBS or preabsorbtion of the primary antibodies with an
excess of ERa or ERb peptide (MC-20, sc-542P; Santa Cruz;
or P-011, Affinity Bioreagents, 1:1 competition for 30 minutes
at room temperature).
Image Analysis
The thickness of the uterine epithelium, the number of
uterine luminal epithelial cell layers, epithelial cell nuclei, and
epithelial cell nuclei with condensed chromatin, and the ap-
pearance of cavities within the epithelial cells were measured
with an image analyzing system [26]. Nine fields were ana-
lyzed from each section (three sections per uterus) in six rats
from each group. In order to more accurately estimate the
expression of ERa in the epithelium of the uterus, again, the
same image analysis system was used. Quantification was
performed on the digitized images of systematic randomly
selected representative fields (a Dplan 20 objective) of
stromal and luminal epithelial cells of the endometrium. Nine
fields were analyzed from each section (two sections per
uterus) in six rats from each group. All ERa-immunostained
luminal epithelial nuclei, regardless of intensity, were scored
as positive. The number of stained (brown-red reaction
product + blue hematoxylin) and unstained nuclei (blue
hematoxylin) per measuring field in sections from control
and treated animals was determined, and also the percent-
age of ERa-immunostained nuclei expressed as ratio of ERa-
immunostained to the total number of epithelial cell nuclei.
Western Blot Analyses
Western blot analyses were performed from uterine tissue
of each in utero–treated offspring [26]. Briefly, 15 mg protein
was separated by SDS-PAGE using 10% gels and electro-
transferred to nitrocellulose membranes. The quality as well
as equal loading of protein blots was determined by Ponceau
S staining of nitrocellulose using a monoclonal antibody
against b-actin (Sigma) at 1:15,000 dilution. Blots were
incubated overnight with polyclonal antibodies against ERa
(MC-20, sc-542; Santa Cruz) at 1:100 dilution or against ERb
(PA1-311, Affinity Bioreagents) at 1:1000 dilution. However,
the commercial antibodies for ERb have been variable in
value; therefore, our data were strengthened by using pos-
itive (heart and liver) and negative (testis) tissue controls,
particularly for the Western analysis of ERb. We compared
the specificity of the ERb immunoreactive bands by using an
additional monoclonal antibody raised against ERb (GR39,
Oncogene Research Products, Darmstadt, Germany) at a
dilution of 1 mg/ml.
The Mr of the immunoreactive bands was determined by
using molecular weight marker protein stocks SDS-PAGE 7b
(Sigma) and a Biotinylated Protein Ladder Detection Pack
(7727S, Cell Signaling Technology, Frankfurt am Main,
Germany).
Specificity of the obtained immunoreactive bands was
assessed by using peptide preabsorbed antiserum against
ERa peptide (MC-20, sc-542P; Santa Cruz, 1:1 competition
for 30 minutes at room temperature) or ERb peptide (P-011,
Affinity Bioreagents, 1:1 competition for 30 minutes at room
temperature) or substituting Tris-buffered saline (TBS, pH
7.5) containing 0.5% nonfat dried milk (NFDM) instead of
primary antibody for ERa and ERb.
A semiquantitative Western blot approach was chosen to
quantify the abundance of ERb. Immunobands of the West-
ern blot analyses were digitized using the raytest digital
camera image analyzing system (raytest, Stranbenhardt,
Germany). The optical density of the ERb and b-actin immu-
nobands was measured by integrating the average 8-bit
gray-scale value of each immunoband using AIDA image
analyzing software (raytest). To standardize for differences
in background intensity between Western blots, the back-
ground 8-bit gray-scale value was subtracted from each
immunoband average 8-bit gray-scale value. The amount
of the ERb message per tissue sample of each case was
expressed as the relative ERb abundance normalized with
that of b-actin expression (ERb/b-actin ratio).
Statistical Analysis
Data analysis was performed using the Statistical Pack-
age for Social Sciences, versions 11.0 for Windows (SPSS,
Chicago, IL) and Sigma Plot 2002 for Windows Version 8.0
(Systat Software GmbH, Erkrath, Germany). Values are
given asmeans ±SD if not otherwise indicated. The statistical
difference of the thickness of uterine luminal epithelium,
number of epithelial cell nuclei, number of epithelial cell
nuclei with condensed chromatin, and the appearance of
cavities within the epithelial cells, as well as the percentage
of ERa-immunostained epithelial nuclei, ERa gene expres-
sion, and ERb gene expression level between the groups
were determined by Mann-Whitney test. Differences were
regarded as significant when the P value was less than .05.
Results
Changes in Morphology of Uterus at Estrus
The differential ability of in utero treatment with BPA and
EE2 to disrupt endometrial histomorphology in offspring after
puberty is shown in Figure 1, A–D. Striking morphologic
changes in the differentiation and stratification of the uterine
epithelium could be observed during estrus from the in utero
BPA-treated animals (Figure 1, C and D) when compared
with the negative control group (Figure 1A). The thickness of
the total epithelium was significantly reduced after exposure
to 50 mg/kg per day BPA (Figure 1,D and E) when compared
with the control group (Figure 1, A and E). The 0.1-mg BPA
dose caused a similar effect, but was less pronounced
(Figure 1, C and E) and not statistically significant to the
control group. Within the 50-mg BPA–treated group the
586 Bisphenol A Exposure Affects Endometrium of Rat Offspring Scho¨nfelder et al.
Neoplasia . Vol. 6, No. 5, 2004
luminal endometrial epithelium was significantly riddled with
cavities containing nuclei with condensed chromatin (Figures
1D and 2, B and C). The luminal endometrial epithelium of
the 0.1-mg BPA–exposed group had a foamy appearance
with significantly increased cavities containing nuclei with
condensed chromatin when compared with the control group
(Figures 1C and 2, B and C). Nuclei were less orderly and
basally located (Figure 1C).
In contrast, the luminal endometrium of the reference
group (EE2-exposed uteri) was mostly characterized by
hypertrophic (columnar cells with less orderly and basally
located nuclei), elongated epithelial cells significantly har-
boring cavities containing nuclei with condensed chromatin
when compared with the control group (Figures 1B and 2,
B and C ).
Expression and Localization of Estrogen Receptors
in the Uterus
ERa Figure 3, A–D, demonstrate representative ERa
immunostainings within the uterine tissue of rat offspring
after in utero treatment with EE2 and 0.1 and 50 mg BPA
compared with the negative controls. Brown-red color,
which indicates ERa immunoreaction, was recognized in
nuclei of both epithelium and stromal cells. The percent-
age of ERa-immunostained, endometrial, luminal epithelial
cell nuclei was significantly increased after EE2 and
50-mg BPA treatment (Figure 3, B, D, and E ). However,
in the 0.1-mg BPA–treated group no significant difference
of the ERa immunostaining in the uteri was observed
compared with the control group (Figure 3, A, C, and E ).
In summary, within the EE2- and 50-mg BPA–treated
group (Figure 3, B and D) the intensity of the immuno-
staining increased in nuclei of the epithelial and stromal
cells compared with the control (Figure 3A) and 0.1-mg
BPA–treated (Figure 3C ) uteri.
However, stronger immunostaining was also recognized
in the cytoplasm of luminal epithelial cells of the BPA 50-mg-
dose group (Figure 3D). This cytoplasmic staining is possibly
due to the staining of newly synthesized ERa. It is interest-
ing to note that the mesenchymal tissues of the 50-mg and
0.1-mg BPA dose group displayed a disorganization of the
ERa-immunostained stroma cells. They are not organized
in a uniform cell layer underlying the epithelium (Figure 3,
C and D ), whereas the ERa-staining pattern frequently
describes a uniform, thick, mesenchymal cell layer underly-
ing the luminal epithelium within the stroma of the EE2-
treated group (Figure 3B ). Control reactions for ERa
immunostaining using an excess of ERa peptide–preab-
sorbed primary antibody or PBS with normal serum in-
stead of antibody first were used to evaluate the
specificity of the ERa immunoreactivity and revealed no
more ERa immunoreactivity (data not shown).
The protein expression of ERa in uteri was compared by
Western blot analysis. We clearly demonstrate that the full-
length ERa expression at 64 kDa is increased during estrus
in the uterus of all female offspring exposed to the 50-mg
dose of BPA and EE2 compared with the negative control
group, whereas ERa expression does not differ between
the 0.1-mg dose of BPA and the control group (Figure 4A).
Within the 0.1-mg dose of BPA and the control group we
could detect only very weak but specific ERa immunobands
of the full-length ERa variant at 64 kDa (Figure 4A). Only two
immunoreactive bands at 56 and 42 kDa from homogenates
of rat uteri from control and 0.1-mg BPA–treated animals
showed strong staining (Figure 4A). Indeed, the anti-ERa
antibody specifically reacted with three bands at 64, 56,
Figure 1. (A–D) Representative high-magnification histology of the rat
offspring uterus at estrus. (A) Control (cornstarch-treated animals) group.
Typical thickened uterine epithelium at estrus stage (*) with orderly and
basally located nuclei. Original magnification, 400. (B) 0.2 mg/kg EE2
(positive control). Pseudostratified hyperplastic epithelium (*, columnar cells
with less orderly and basally located nuclei) harboring cavities (arrows).
Original magnification, 400. (C) 0.1 mg/kg per day BPA. Decreased luminal
endometrial epithelium thickness with a foamy appearance (*) and cavities
(arrows). Nuclei are less orderly and basally located. Original magnification,
400. (D) 50 mg/kg per day BPA. Significantly reduced thickness of the total
epithelium (*). The luminal endometrial epithelium is riddled with cavities
containing nuclei with condensed chromatin (arrows). Original magnification,
400. (E) Statistical analysis of height (m) of the luminal epithelial cell layers
from rat offspring after in utero treatment with BPA or EE2 at estrus stage.
Values are based on analysis of three sections for each uterine specimen
(six from each group). Quantification was performed on the digitized images
of 10 systematic, randomly selected, representative fields and are reported
as the mean ± SD. Co, control group, 31.0 ± 3.9 m, n = 6; EE2, 0.2 mg/kg
per day 17a-ethinyl estradiol group, 33.2 ± 9.4 m, n = 6; BPA0.1, 0.1 mg/kg
per day BPA, 27.8 ± 1.8 m, n = 6; BPA50, 50 mg/kg per day BPA, 19.2 ±
6.0 m, n = 6.
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and 42 kDa from homogenates of rat uteri (Figure 4, A–C)
because binding to all immunopositive bands was eliminated
when the antibody was preincubated with antigen ERa
peptide (Figure 4B). Substituting TBS containing 0.5%
NFDM instead of primary antibody for ERa led to no more
immunoreactivity (Figure 4C).
ERb Figure 5, A–D, demonstrates representative ERb
immunostainings within the uterine tissue of rat offspring
after in utero treatment with EE2 and 0.1 and 50 mg BPA
compared with the negative controls (Figure 5A). The brown-
red color, which indicates ERb immunoreaction, was recog-
nized dominantly in stromal cells of the mesenchyme. ERb
immunostaining was significantly decreased after EE2
(Figure 5B) and BPA treatment (0.1 mg BPA, Figure 4C;
50 mg BPA, Figure 4D) when compared with the control
group (Figure 5A).
Control reactions for ERb immunostaining using an ex-
cess of ERb peptide–preabsorbed primary antibody or PBS
with normal serum instead of antibody first were used to
evaluate the specificity of the ERb immunoreactivity and
revealed no more ERb immunoreactivity (data not shown).
Again, the protein expression of ERb in uteri was com-
pared by Western blot analysis. We clearly demonstrate that
the ERb expression at 53 kDa is decreased during estrus at
the protein level in the uterus of all female offspring exposed
to EE2 and the 0.1- and 50-mg dose of BPA compared with
the negative control group (Figure 6, A and C). Within the
0.1- and 50-mg dose of BPA we could detect only a very
weak ERb immunoband.
The anti-ERb antibody (PA1-311, Affinity Bioreagents)
specifically reacted with one band at 53 kDa from homoge-
nates of rat uteri (Figure 6, A and B), because binding to all
immunopositive bands at 53 kDa was eliminated when the
Figure 2. (A–C) Statistical analysis of epithelial cell nuclei, epithelial cell nuclei with condensed chromatin, and the appearance of cavities within the epithelial cells
from rat offspring after in utero treatment with BPA or EE2 at estrus stage. Values are based on analysis of three sections for each uterine specimen (six from each
group). Quantification was performed on the digitized images of nine systematic, randomly selected, representative fields and are reported as the mean ± SD. (A)
Number of epithelial cell nuclei: Co, control group, 18.0 ± 4.0, n = 6; EE2, 0.2 mg/kg per day 17a-ethinyl estradiol group, 33.5 ± 12.78, n = 6; BPA0.1, 0.1 mg/kg per
day BPA, 30.5 ± 6.8, n = 6; BPA50, 50 mg/kg per day BPA, 33.8 ± 3.7, n = 6. (B) Number of epithelial cell nuclei with condensed chromatin: Co, control group, 8.5 ±
3.9, n = 6; EE2, 0.2 mg/kg per day 17 a-ethinyl estradiol group, 20.0 ± 12.4, n = 6; BPA0.1, 0.1 mg/kg per day BPA, 22.7 + 6.1, n = 6; BPA50, 50 mg/kg per day
BPA, 26.2 ± 7.6, n = 6. (C) Appearance of cavities within the epithelial cells: Co, control group, 7.7 ± 3.2, n = 6; EE2, 0.2 mg/kg per day 17a-ethinyl estradiol group,
15.2 ± 3.9, n = 6. BPA0.1, 0.1 mg/kg per day BPA, 16.2 ± 2.3, n = 6; BPA50, 50 mg/kg per day BPA, 14.4 ± 3.4, n = 6.
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antibody was preincubated with antigen ERb peptide (data
not shown). Substituting TBS containing 0.5%NFDM instead
of primary antibody for ERb led to no more immunoreactivity
(data not shown).
Additional control experiments investigated the specificity
of the immunoreactions against ERb at 53 kDa within the
Western analysis by comparing two different commercial
antibodies. Both antibodies raised against ERb revealed
the same specific immunoreactions in positive (uterus, liver,
and heart) and negative (testis) tissue controls (Figure 6B).
Discussion
In the uterus, estrogens stimulate uterine epithelium prolif-
eration in vivo [44] and play a critical role in uterine epithelial
Figure 3. (A–D) Representative high-magnification ERa immunostaining
within the uterine tissue of rat offspring after in utero treatment with EE2 and
0.1 and 50 mg BPA compared with the negative controls. ERa immuno-
reaction was recognized in nuclei of both epithelium (arrowheads) and
stromal cells (arrows). (A) Control (cornstarch-treated animals) group. Weak
ERa immunoreaction in nuclei of both epithelium and stromal cells. Less
ERa-immunostained luminal epithelium cell nuclei. Original magnification,
400. (B) 0.2 mg/kg per day EE2 (positive control). Significantly increased
population of ERa-immunostained uterine luminal epithelial cell nuclei, as
well as a strongly immunostained stromal cell pattern frequently describing a
uniform, thick mesenchymal cell layer underlying the luminal epithelium.
Original magnification, 400. (C) 0.1 mg/kg per day BPA. Weak ERa
immunoreaction in nuclei of both epithelium and stromal cells. Less ERa-
immunostained luminal epithelium cell nuclei. Original magnification, 400.
(D) 50 mg/kg per day BPA. Significantly increased population of ERa-
immunostained uterine luminal epithelial cell nuclei, as well as strongly
immunostained stromal cells, which are not organized in a uniform cell layer
underlying the epithelium. Stronger immunostaining was also recognized in
the cytoplasm of luminal epithelial cells. Original magnification, 400. (E)
Image analysis score of positive ERa-immunostained uterine luminal
epithelial cells. Shown is the percentage of ERa-immunostained uterine
epithelial cell nuclei. Values are based on analysis of nine fields from each
section (two sections per uterus) in six rats from each group and are reported
as the mean ± SD. Co, control (cornstarch-treated animals) group, 57 ± 19%,
n = 6; EE2, 0.2 mg/kg per day 17a-ethinyl estradiol group, 90 ± 4%, n = 6;
BPA0.1, 0.1 mg /kg / day BPA, 67 ± 7%, n = 6; BPA50, 50 mg/kg per day
BPA, 95 ± 15%, n = 6.
Figure 4. Representative Western blot analyses of ERa expression of uterine
protein at estrus stage of female Sprague-Dawley offspring exposed to 17a-
ethinyl estradiol and bisphenol A in utero. Gravid dams were fed by gavage
on gestation days 6 through 21 with either 2% cornstarch (negative control;
CO) at 10 ml/kg per day, 0.2 mg/kg per day EE2 (EE2), used as a positive
control, or 0.1 mg/kg per day BPA (BPA0.1) or 50 mg/kg per day BPA
(BPA50). The female offspring were then sacrificed in estrus at 4 months of
age. (A) The full-length ERa expression at 64 kDa is increased in all female
offspring exposed to EE2 and the 50-mg dose of BPA compared with the
negative control group. Within the 0.1-mg dose of BPA and the control group
only very weak but specific ERa immunobands of the full-length ERa variant
at 64 kDa could be detected. Only two immunoreactive bands at 56 and 42
kDa from homogenates of rat uteri from all treated animals showed strong
staining. Protein loading was normalized to -actin using a monoclonal
primary antibody at a 1:15,000 dilution (Sigma), which was specific for a band
at 42 kDa. The anti-ERa antibody specifically reacted with three bands at 64,
56, and 42 kDa from homogenates of rat uteri. (B) Binding to all immuno-
positive bands was eliminated when the antibody was preincubated with
antigen ERa peptide. (C) Substituting TBS containing 0.5% NFDM (F 1.Ab)
instead of primary antibody (+ 1.Ab) for ERa led to no more immunoreactivity.
Protein, in the amounts of 14, 30, and 15 g, was loaded.
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growth, morphogenesis, cytodifferentiation, and secretory
activity [45].
Little is known about the deleterious effects in the uterus
after prenatal exposure to BPA. This lack of data might exist
because most traditional endpoints of toxicity may not be
sensitive enough or not detectable until sexual maturity [39].
Indeed, we previously observed that the reduction in abso-
lute uterine weight in the 0.1-mg BPA–treated group during
estrus was qualitatively similar to that seen with the refer-
ence estrogen, whereas the absolute uterine weight of
the 50-mg/kg group was similar to negative controls [40].
The decreases were no longer evident after calculation of the
relative uterine weights (corrected for body weight), indicat-
ing that the effect of low doses of BPA on the uterus is very
modest [40]. We demonstrated that birth weight was not
affected by in utero exposure to either dose of BPA, which is
in contrast to a decreased birth weight noted in offspring
exposed to the reference estrogen [40].
Additionally, we recently reported finding a greater per-
centage of cycles with longer estrus phases in the 50-mg/kg
BPA dose group. This effect was qualitatively similar to that
observed with the reference estrogen, which caused almost
persistent estrus. Likewise, the high dose of BPA led to a
greater percentage of longer estrous cycles. These findings
stimulated us to conduct the present experiments.
For the first time, we demonstrate striking morphologic
changes of the uterine epithelium from the in utero BPA–
treated animals during estrus (Figure 1, C–D, and Figure 2,
A–C), which are similar to DES-specific disruption patterns
[46]. In accordance with previous reports studying the effects
of DES [46], we noted uterine disorganization, irregular
Figure 5. (A–D) Representative high magnification ER immunostaining
within the uterine tissue of rat offspring after in utero treatment with EE2 and
0.1 and 50 mg BPA compared with the negative controls. The brown-red
color, which indicates ER immunoreaction, was recognized dominantly in
stromal cells of the mesenchyme (asterisks). (A) Control (cornstarch-treated
animals) group. Distinct ER immunoreaction in stromal cells of the
mesenchyme. Original magnification, 200. (B) 0.2 mg/kg per day EE2
(positive control). Weak immunostained mesenchyme. Original magnification,
200. (C) 0.1 mg/kg per day BPA. Decreased ER immunoreactions in
stromal cells. Original magnification, 200. (D) 50 mg/kg per day BPA. No
ER immunoreactions within the uterus. Original magnification, 200.
Epithelium (arrow heads).
Figure 6. Representative semiquantitative Western blot approach of ER
expression of uterine protein at estrus stage of female Sprague-Dawley
offspring exposed to 17a-ethinyl estradiol and bisphenol A in utero. Gravid
dams were fed by gavage on gestation days 6 through 21 with either 2%
cornstarch (negative control; CO) at 10 ml/kg per day, 0.2 mg/kg per day EE2
(EE2), used as a positive control, or 0.1 mg/kg per day BPA (BPA0.1) or
50 mg/kg per day BPA (BPA50). The female offspring were then sacrificed
in estrus at 4 months of age. (A) We clearly demonstrate that the ER
expression at 53 kDa is decreased during estrus at the protein level in the
uterus of all female offspring exposed to EE2 and the 0.1- and 50-mg dose of
BPA compared with the negative control group. Within the 0.1- and 50-mg
dose of BPA, we could detect only a very weak ER immunoband. Protein
loading was normalized to -actin using a monoclonal primary antibody at
1:15,000 dilution (Sigma), which was specific for a band at 42 kDa. (B)
Additional control experiments investigated the specificity of the immuno-
reactions against ER at 53 kDa within the Western analysis by comparing
two different commercial antibodies (PA1-311, Affinity Bioreagents, and
GR39, Oncogene Research Products). Both antibodies raised against ER
revealed the same specific immunobands in positive (uterus, liver, and heart)
and negative (testis) tissue controls. (C) Statistical analysis of the semi-
quantitative Western blot approach of ER expression of uterine protein at
estrus stage of all female Sprague-Dawley offspring. The optical density of
the ER and -actin immunobands was measured by integrating the average
8-bit gray-scale value of each immunoband. To standardize for differences in
background intensity between Western blots, the background 8-bit gray scale
value was subtracted from each immunoband average 8-bit gray-scale value.
The amounts of the ER message per tissue sample of each case were
expressed as the relative ER abundance normalized with that of -actin
expression (ratio ER/-actin) and are reported as the mean ± SD. The
statistical analysis revealed that the ER expression is decreased during
estrus at the protein level in the uterus of all female offspring exposed to EE2
and the 0.1- and 50-mg dose of BPA compared with the negative control
group.
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nuclei, and the appearance of cavities in the uteri of all BPA-
treated animals [47]. Normally, the uterine luminal epithelium
is the tallest at estrus [46]. The thickness of the total
epithelium was significantly reduced following exposure to
50 mg/kg BPA (Figure 1, D and E). The 0.1-mg BPA dose
caused a similar effect, but was less pronounced (Figure 1,
C and E). These abnormalities in the uterus of rat offspring
are similar to the abnormalities found in rodents and humans
after DES treatment [47]. Hypoplastic uteri were observed in
human offspring after DES exposure [48–50]. Salle et al.
[51] demonstrated by transvaginal ultrasound that particu-
larly in the luteal phase, the thickness of the human endo-
metrium was decreased significantly in patients with prenatal
DES–exposed uteri. Neonatal DES exposure inhibited en-
dometrial gland development and elicited a hypotrophic/
hypoplastic response in the rat uterus [52–54]. In contrast,
in utero treatment with EE2 led to a hypertrophic response
in the uterus (Figure 1B). In the EE2-exposed uteri, a
characteristic histopathologic profile [43,55–57], including
hypertrophic elongated luminal endometrium epithelial cells
with less orderly and basally located nuclei and cavities
(Figures 1B and 2, A–C), was detected.
The observed morphologic differences between the EE2-
and BPA-treated animals are not unexpected because pre-
vious studies already demonstrated similar differences of
uterine disruption at the histologic level when exposed to
DES or E2 [58–64]. Therefore, by summarizing all of these
results from a number of studies, including our work, we have
to question the unitary view of estrogen action. There are
substantial differences in the potencies of different estrogens
that result from complex biological and pharmacokinetic
dynamics, such as their receptor-binding affinities and ab-
sorption, including method (e.g., oral route vs. subcutaneous
injection) and time point (developmental stage) of adminis-
tration, first-pass metabolism, plasma protein binding, and
elimination [64,65].
Because of the striking morphologic changes of the
uterine epithelium after in utero treatment with BPA and
EE2, we studied the expression of ERa and ERb to elucidate
the possible mechanisms for the cellular effects. Most of the
estrogenic effects on the uterus are mediated by ERa, which
is the predominant subtype in the normal uterus and which
regulates epithelial morphogenesis, cytodifferentiation, and
secretory activity. ERa is fundamental for development and
growth of the uterus. Recently, however, it has been dem-
onstrated that ERb acts as a modulator of the ERa-mediated
effects in the uterus. ERb can modulate ERa-mediated gene
transcription leading to antiproliferative function in the uterus
[43]. The importance of both ERs for the uterus was also
indicated using the ER knockout mice, aERKO, bERKO, and
abERKO [66–68].
In comparison with recent studies [69], ERa immunoreac-
tivity was confined to the nuclei of both endometrial epitheli-
um and stromal cells in the rat uterus at estrus stage. We
clearly demonstrate that the anti-ERa antibody specifically
reacted with three bands at 64, 56, and 42 kDa from homo-
genates of rat uteri (Figure 4, A–C), which is in accordance
with our previous study [26]. These shorter bands (56 and
42 kDa) are derived from the alternative usage of initiation
ATG or splicing [70, 71]. Specificity of immunoreactivity was
analyzed by using peptide-preabsorbed antibodies
(Figure 4B) and substituting TBS instead of primary antibody
for ERa (Figure 4C). In the EE2- and 50-mg BPA–treated
groups, at the level of protein expression, the intensity of the
ERa immunostaining of the full-length ERa variant at 64 kDa
increased (Figures 3,B,D, andE, and 4A) in comparison with
the control (Figures 3, A and E, and 4A) and 0.1-mg BPA–
treated uteri (Figure 3, C and E, and 4A), where only very
weak immunoreactions of the full-length ERa variant at 64
kDa (Figure 4A) could be detected by Western blot analysis
and immunohistochemistry, respectively. These results
clearly confirm data from previous studies in neonatal and
immature rodents where 17b-estradiol, BPA, or DES treat-
ment increased ERa mRNA expression, the number of
positively ERa-immunostained epithelial cells, and the inten-
sity of ERa-immunostaining within the uterus [43,72–75].
Stronger immunostaining was also recognized in the cyto-
plasm of luminal epithelial cells of the 50-mg BPA dose group
(Figure 3D), which is possibly due to the staining of newly
synthesized ERa that has been proven by a semiquantitative
RT-PCR analysis (G. Scho¨nfelder, unpublished data).
Nevertheless, in the present study it was unclear what
caused the differences of uterine disruption at the histologic
level between BPA, especially the 50-mg dose group, and
the reference dose (EE2). There could be many explana-
tions. One explanation is related to a dysregulation of the
ERb. As already stated, ERb acts as a transdominant re-
pressor on ERa transcriptional activity at subsaturating
concentrations of endogenous 17b-estradiol (E2) in the
uterus [76] by forming heterodimers with the ERa [77,78].
Thus, ERb can oppose ERa effects on epithelial cell growth.
This information stimulated us to study the expression and
localization of ERb in all uteri. Immunostaining revealed
decreased immunoreactivity against ERb after EE2
(Figure 5B) and BPA treatment (0.1 mg BPA, Figure 5C,
and 50 mg BPA, Figure 5D) when compared with the control
group (Figure 5A). The protein expression of ERb in uteri was
again compared by Western blot analysis. Western blot
analysis clearly demonstrated downregulation of ERb during
estrus in the uterus of all female offspring exposed to EE2,
the 0.1-mg and the 50-mg dose of BPA compared with the
negative control group (Figure 6, A and C). The downregu-
lation of ERb within the in utero EE2–exposed rats would
explain our morphologic observation of the uterine epitheli-
um hypertrophy (Figure 1B). Indeed, these results are con-
sistent with previous studies in rodents where estrogen
treatment decreased ERb expression in the uterus [43,79].
ERb was downregulated and ERa becomes fully functional,
leading to increased cell proliferation and enhanced respon-
siveness to E2 [43]. In contrast to the observed morphologic
changes in the EE2 group we found significantly reduced
thickness of the total epithelium and similar effects after
exposure to 50 mg/kg per day BPA (Figure 1, D and E),
but less pronounced after exposure with 0.1 mg BPA
(Figure 1, C and E). One likely explanation for the phenom-
enon within the 0.1 mg/kg per day BPA group is that ERa
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expression is not highly enough induced by the low dose of
BPA (Figures 3,C and E, and 4A). Therefore, ERa is not fully
functional and subsaturating concentrations of the ovarian
estradiol cannot stimulate uterine cell proliferation, even if
ERb expression is decreased (Figures 5C and 6, A and C).
However, within the 50 mg/kg per day BPA group we would
assume the same morphologic changes as in the EE2 dose
group because of its ER’s expression pattern. ERa is highly
upregulated and ERb was much more downregulated com-
pared with the EE2 group. Nevertheless, we observed a
hypoplastic epithelium. Until now, we have only one sugges-
tion to explain this controversial effect.
We suggest that differences in sensitivity of the uterus to
different estrogens and xenoestrogens may be attributed to
differences in ERa and ERb distribution and regulation over
developmental periods. It has been demonstrated, e.g., that
ERa and ERb are highly regulated molecules whose tran-
scriptional activity can be regulated by the nature of the bound
ligand. Thus, different compounds induce different structural
alterations within the estrogen receptors [80,81]. After acti-
vation, the ERa forms a dimer with/without the ERb; nuclear
receptor coactivators associate in a ligand-dependent man-
ner with estrogen receptors, and they enhance ligand-depen-
dent transcriptional activation. This activation will alter the
differentiation and proliferation of the uterine epithelial cell by
influencing target gene transcription, such as the progester-
one receptor. Expression levels of the coactivators determine
whether a given ER–ligand complex will manifest antagonist
or agonistic activity in a particular cell [81]. Therefore, hor-
monal treatment could possibly represent an induction of
uterine epithelial coactivators, perhaps in selected cells, or
repression of stromal coactivator mRNA, which influence
expression of genes important for uterine epithelial growth.
In summary, these results clearly indicate that in utero
exposure (not neonatal) [74] of rats to BPA promotes uterine
disruption by influencing expression and distribution of the
estrogen receptors ERa and ERb. BPA might influence the
development, growth, and function of the uterus through both
receptors. Although it has been demonstrated that ERa
plays a major role in the differentiation and proliferation of
the uterine epithelium, we can demonstrate that ERb can
modulate the effects of the uterine dominant ERa. Never-
theless, in the present study it remains unclear what caused
the differences of uterine disruption at the histologic level
between BPA, especially the 50-mg dose group, and the
reference dose (EE2). Therefore, further studies for clarify-
ing the effects of BPA and EE2 on the regulation of uterine
progesterone receptor and coactivators are needed.
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